IRAK4 Degrader Ternary Complex for IL-1R/TLR Pathway Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoinflammatory/autoimmune diseases and hematological malignancies targeting the IL-1R/TLR pathway are inadequate, with a high unmet need for more effective therapeutics.
Innovation Solution
Administration of the IRAK4 degrader 5-((1R,4R)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-(3-(difluoromethyl)-1-((1r,4R)-4-((4-((3-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-4-yl)prop-2-yn-1-yl)oxy)piperidin-1-yl)methyl)cyclohexyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (Compound A) to selectively degrade IRAK4 via the ubiquitin-proteasome system, forming a ternary complex with CRBN and IRAK4 to inhibit downstream proinflammatory cytokine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments targeting the IL-1R/TLR pathway are used, then some therapeutic effect is achieved, but the treatment effectiveness is inadequate and unmet need remains high
Solution Approach 1:
The patent employs parameter changes by developing IRAK4 degraders with optimized pharmacokinetic parameters (Cmax, AUC0-24) and degradation potency (DC50 values). Compound A achieves Cmax up to 561 ng/mL and AUC0-24 up to 11,700 ng*hr/mL, with DC50 values in the low nM range across species, representing significant parameter improvements over prior treatments.
Solution Approach 2:
The invention uses composite molecular structures combining a CRBN-targeting ligand, a linker, and an IRAK4-targeting ligand to create heterobifunctional degraders. This composite approach enables simultaneous binding to both CRBN and IRAK4, forming a ternary complex that mediates selective degradation and provides superior therapeutic effects compared to monofunctional agents.
2Reliability
If higher doses of Compound A are administered to achieve greater IRAK4 degradation, then therapeutic efficacy improves, but the risk of adverse effects increases
Solution Approach 1:
The patent optimizes the dosage parameter to achieve therapeutic efficacy while minimizing adverse effects. The NOAEL in dogs was determined to be 60 mg/kg/day, corresponding to Cmax of 561 ng/mL and AUC0-24 of 11,700 ng*hr/mL. The recommended human starting dose of 150-300 mg once daily is based on these parameters, providing a safe and effective dosing regimen.
Solution Approach 2:
The degrader utilizes the cell's own ubiquitin-proteasome system to degrade IRAK4, achieving selective target degradation without requiring external delivery mechanisms. The compound forms a ternary complex with CRBN and IRAK4, recruiting the endogenous degradation machinery to selectively eliminate the target protein, thereby reducing off-target effects.
3Adaptability or versatility
If IRAK4 degrader is designed to achieve potent degradation across species, then translational potential improves, but the molecular complexity increases
Solution Approach 1:
The patent achieves universality by designing a heterobifunctional degrader that can bind to CRBN and degrade IRAK4 across multiple species including humans, dogs, and mice. The compound demonstrates consistent DC50 values in the low nM range across species, indicating broad translational potential and species-independent mechanism of action despite the complex molecular structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Compound A achieves significant IRAK4 degradation across species, reducing inflammatory markers and cytokines, demonstrating potent and reversible effects in murine and canine models, with therapeutic benefits in autoimmune diseases and hematological malignancies.
Implementation Method 1
Compound A is a potent, highly selective, orally administered heterobifunctional small molecule therapeutic targeting IRAK4 and the E3 ligase CRBN to mediate the selective degradation of IRAK4 via the ubiquitin-proteasome system
Data Source
AI summary
The present invention relates to a method of treating autoimmune/autoinflammatory diseases and hematological malignancies in a subject.